Trial Profile
ACROSTUDY, a Pfizer-sponsored non-interventional post marketing study on the long-term outcomes of pegvisomant therapy in patients with acromegaly
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACROSTUDY
- Sponsors Pfizer
- 31 Mar 2022 Results published in the Journal of Endocrinological Investigation
- 01 Mar 2020 Results (n=2077) of Retrospective cohort analysis of data from ACROSTUDY, assessing All-cause mortality in patients with acromegaly treated with pegvisomant, published in the European Journal of Endocrinology
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society